BRPI0814685A2 - variantes com splicing de cd44 em doenças neurodegenerativas - Google Patents

variantes com splicing de cd44 em doenças neurodegenerativas

Info

Publication number
BRPI0814685A2
BRPI0814685A2 BRPI0814685A BRPI0814685A BRPI0814685A2 BR PI0814685 A2 BRPI0814685 A2 BR PI0814685A2 BR PI0814685 A BRPI0814685 A BR PI0814685A BR PI0814685 A BRPI0814685 A BR PI0814685A BR PI0814685 A2 BRPI0814685 A2 BR PI0814685A2
Authority
BR
Brazil
Prior art keywords
neurodegenerative diseases
splicing variants
splicing
variants
neurodegenerative
Prior art date
Application number
BRPI0814685A
Other languages
English (en)
Inventor
Pinner Elhanan
Laudon Moshe
Zisapel Nava
Original Assignee
Neurin Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurin Pharmaceuticals 1991 Ltd filed Critical Neurin Pharmaceuticals 1991 Ltd
Publication of BRPI0814685A2 publication Critical patent/BRPI0814685A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
BRPI0814685A 2007-07-10 2008-07-10 variantes com splicing de cd44 em doenças neurodegenerativas BRPI0814685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92970607P 2007-07-10 2007-07-10
PCT/IB2008/052786 WO2009007934A2 (en) 2007-07-10 2008-07-10 Cd44 splice variants in neurodegenerative diseases

Publications (1)

Publication Number Publication Date
BRPI0814685A2 true BRPI0814685A2 (pt) 2019-09-24

Family

ID=40229192

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814685A BRPI0814685A2 (pt) 2007-07-10 2008-07-10 variantes com splicing de cd44 em doenças neurodegenerativas

Country Status (16)

Country Link
US (2) US9018180B2 (pt)
EP (1) EP2167692B1 (pt)
JP (1) JP2010532989A (pt)
KR (1) KR20100044793A (pt)
CN (1) CN101821407B (pt)
AU (1) AU2008273713B2 (pt)
BR (1) BRPI0814685A2 (pt)
CA (1) CA2692861A1 (pt)
EA (1) EA201070108A1 (pt)
ES (1) ES2423182T3 (pt)
HK (1) HK1145856A1 (pt)
IL (1) IL203130A (pt)
MX (1) MX2010000236A (pt)
NZ (1) NZ582390A (pt)
WO (1) WO2009007934A2 (pt)
ZA (1) ZA201000083B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019974B1 (ru) 2007-12-19 2014-07-30 Кансер Рисерч Текнолоджи Лимитед 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
EP2531502B1 (en) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EA201391387A1 (ru) 2011-03-24 2014-01-30 Неурим Фармасьютикалс (1991) Лтд. Нейропротекторные пептиды
US9399779B2 (en) * 2011-06-08 2016-07-26 The Corporation Of Mercer University Alternative splicing constructs and methods of use
CN104277092B (zh) * 2013-07-12 2017-10-31 天津医科大学 用于预防和/或治疗老年性痴呆的β片层阻断肽
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2016033774A1 (zh) 2014-09-04 2016-03-10 天津医科大学 用于预防和/或治疗阿尔茨海默病的β片层阻断肽
CN107815438A (zh) * 2017-08-02 2018-03-20 清华大学 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物
CN117377777A (zh) * 2021-05-11 2024-01-09 纽瑞姆制药(1991)有限公司 诊断和治疗具有2号染色体2:107,510,000-107,540,000基因座单核苷酸多态性受试者的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6150162A (en) 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
IL133647A0 (en) 1999-06-08 2001-04-30 Yissum Res Dev Co Novel cd44 variant
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
DK1407044T4 (en) * 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
EP1383543A4 (en) 2001-03-23 2006-06-21 Agy Therapeutics Inc USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS
CN1511040A (zh) 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
US7833779B2 (en) * 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection
WO2005030947A2 (en) * 2003-09-30 2005-04-07 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
ATE495269T1 (de) 2005-06-16 2011-01-15 Evotec Neurosciences Gmbh Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen

Also Published As

Publication number Publication date
MX2010000236A (es) 2010-06-02
AU2008273713A1 (en) 2009-01-15
EA201070108A1 (ru) 2010-06-30
JP2010532989A (ja) 2010-10-21
WO2009007934A2 (en) 2009-01-15
US20110172286A1 (en) 2011-07-14
WO2009007934A3 (en) 2009-05-07
US20150266940A1 (en) 2015-09-24
ES2423182T3 (es) 2013-09-18
EP2167692B1 (en) 2013-05-22
NZ582390A (en) 2012-05-25
KR20100044793A (ko) 2010-04-30
US9416166B2 (en) 2016-08-16
EP2167692A2 (en) 2010-03-31
HK1145856A1 (en) 2011-05-06
CN101821407A (zh) 2010-09-01
CA2692861A1 (en) 2009-01-15
CN101821407B (zh) 2013-09-18
ZA201000083B (en) 2011-03-30
AU2008273713B2 (en) 2014-07-03
US9018180B2 (en) 2015-04-28
IL203130A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
BRPI0814685A2 (pt) variantes com splicing de cd44 em doenças neurodegenerativas
SMT201500186B (it) Autoanticorpi umani anti-alfa-sinucleina
ATE481948T1 (de) Linseneinführsystem
ATE427720T1 (de) Linseneinfuhrsystem
ITPD20070425A1 (it) Asta per occhiali
BRPI0920743A2 (pt) ribonucleases terapeuticas
DK2147106T3 (da) Expressionssystem
DE602007007552D1 (de) Multiprozessorsystem
DE602006003616D1 (de) Optisches System
DE602007010314D1 (de) Glaspostenverteilung
DE112006004052A5 (de) Anzeigegerät
RU60470U8 (ru) Автобус i класса
FR2924587B1 (fr) Presentoir
FI8011U1 (fi) Heijastin
UA15503S (uk) Міст передній ведучий
UA12280S (uk) Автобус малий міжміський 2-го класу
UA17849S (uk) Автобус міський
ITTO20060079U1 (it) Occhiali da nuoto
ITMI20060429U1 (it) Occhiali da nuoto
ITTO20060036U1 (it) Occhiali da nuoto
CN300862083S (zh) 眼镜
ES1066007Y (es) Gafas
FI20080332A0 (fi) Terapeuttisia molekyylejä
TH0901001420A (th) ป้ายรถโดยสาร
FI20075969A0 (fi) Pysäköintijärjestelmä

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.